AdipoGen Life Sciences

anti-LRP5/6, mAb (rec.) (Heldy-1-4)

CHF 480.00
In stock
AG-27B-0019-C100100 µgCHF 480.00
More Information
Product Details
Synonyms Low-density Lipoprotein Receptor-related Protein 5; LRP-5; Low-density Lipoprotein Receptor-related Protein 6; LRP-6
Product Type Recombinant Antibody
Properties
Clone Heldy-1-4
Isotype Human IgG2λ.
Source/Host Produced without the use of animals. Purified from HEK 293 cell culture supernatant.
Immunogen/Antigen Recombinant mouse LRP6.
Application

Flow Cytometry: 1/100 dilution

Crossreactivity Human
Mouse
Specificity

Recognizes human and mouse LRP5 & LRP6.

Purity ≥95% (SDS-PAGE)
Purity Detail Protein A-affinity purified.
Concentration 1mg/ml
Formulation Liquid. In PBS containing 10% glycerol.
Isotype Negative Control

Fc (human) IgG2 Control (rec.)

Other Product Data

anti-LRP5/6 (human), mAb (rec.) (Heldy-1-4) is composed of human variable regions (VH and VL) (λ-chain) of immunoglobulin fused to the human lgG2 Fc domain.

Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description

Wnt/β-catenin signaling acts as a regulator of tissue development and homeostasis. Wnt ligands bind to a member of the Frizzled family of seven-transmembrane proteins and to either highly homologous low-density lipoprotein related receptors 5 (LRP5) or LRP6. Low-density lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor (LDLR) family. LRP5 and LRP6 are expressed in most human tissues and is composed of three distinctive cell-surface protein domains, including (1) LDL receptor (LDLR) type A repeats; (2) an epidermal growth factor (EGF)-like domain; and (3) a YWTD (Tyr-Trp-Thr-Asp)-type β propeller domain. LRP6 is inhibited by the Dickkopf protein Dkk1 bound to their partners Kremen. Sclerotin also acts as an inhibitor of LRP5/6 through LRP4. LRP6 is involved in cell differentiation, proliferation and migration during embryonic development and in the pathogenesis of different cancer types. LRP6 plays a major role in metabolic regulation, specifically in the nutrient-sensing pathway. Patients carrying an LRP6 mutation exhibit high serum LDL cholesterol and triglycerides, hypertension, high fasting blood glucose levels, a prevalence of diabetes and low bone density. LRP6 mutations have also been associated with diseases such as Alzheimer's and degenerative joint diseases. LRP5, low-density-lipoprotein-receptor-related protein 5, is a determinant for bone mineral density and plays a role in osteoporosis. LRP5 is aso involved in vitreoretinopathy.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.